HCA Healthcare’s payer shift pressures profits despite revenue growth

Payer mix became the quarter’s main pressure

HCA Healthcare’s third-quarter results show that revenue growth did not translate into net-income growth: the company reported revenue of $19.849 billion, up 3.6% from $19.161 billion, while net income attributable to the company declined 3.9% to $1.579 billion. HCA said an increase in uninsured volume—primarily among patients who lost coverage on health insurance exchanges—reduced income before income taxes by approximately $400 million during the quarter. HCA Healthcare, third-quarter 2026 results

The operating result was more resilient. Adjusted EBITDA, a non-GAAP measure, increased 1.2% to $3.918 billion, while operating cash flow rose to $4.461 billion from $4.416 billion a year earlier. Diluted earnings per share increased 4.5% to $7.27; diluted earnings per share, as adjusted, a non-GAAP measure, increased 3.7% to $7.22. The results included $13 million of gains on facility sales, or $0.05 per diluted share. Nasdaq, HCA Healthcare third-quarter 2026 results

Volume growth offset weaker surgery activity

Same-facility admissions increased 2.7%, same-facility equivalent admissions rose 3.0%, and emergency-room visits increased 5.1%. Those gains did not extend to surgeries: same-facility inpatient surgeries declined 1.4% and outpatient surgeries fell 3.7%. Same-facility revenue per equivalent admission increased 0.6%. HCA Healthcare, third-quarter 2026 results

HCA nevertheless reported improved cost results and a modestly higher net benefit from Medicaid supplemental payment programs. The combination suggests that admission growth and cost performance partly absorbed the payer-mix pressure, although HCA did not provide enough evidence in the reviewed release to establish the durability of that offset. FinancialContent, HCA Healthcare third-quarter 2026 results

Policy exposure moved from rhetoric to earnings

CEO Sam Hazen said HCA continued to provide high-quality care despite challenges arising from federal policy changes and believed the company was positioned to end the year positively. The disclosure of a roughly $400 million pretax impact tied to exchange coverage losses provides a more concrete measure of policy-related payer-mix exposure than the company’s year-end assessment alone. Nasdaq, HCA Healthcare third-quarter 2026 results

The next verifiable checkpoint is HCA’s updated full-year operating guidance and its fourth-quarter results. Subsequent disclosure may help determine whether higher uninsured volume, slower surgery growth or improving costs become the dominant drivers of the year-end outcome.